Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3073–3096 of 145,503 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: End Stage Renal Disease and Kidney Transplantation
Interventions: COACH Program; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Traumatic Brain Injury, Coping Skills
Interventions: Telemedicine Brain Injury Coping Skills; Behavioral
Lead sponsor: Rehabilitation Hospital of Indiana; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Heart Failure
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Impulse Control Disorders
Interventions: Escitalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Continuous Glucose Monitor, Usual Care; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cardiovascular Diseases, Myocardial Infarction, Heart Diseases, Death, Sudden, Cardiac
Interventions: Cardiopulmonary Resuscitation, Automatic External Defibrillation; Other · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 7,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy, Hypercholesterolemia
Interventions: Enlicitide Chloride, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Dermatitis, Atopic
Interventions: Nanodox 1% (doxycycline monohydrate hydrogel); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Peanut Hypersensitivity
Interventions: Peanut protein; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 16 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Leukemia, Lymphoma
Interventions: Rituximab, Cyclophosphamide, Lenalidomide, Pentostatin; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Epilepsy
Interventions: Vinpocetine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hereditary Diseases, Critical Illness
Interventions: Genome sequencing; Genetic
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Opioid-use Disorder
Interventions: BupreCare, Buprenorphine/naloxone, MEMS; Device · Drug · Other
Lead sponsor: MedicaSafe, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: San Diego, California • Baltimore, Maryland

Conditions: Mindfulness, Occupational Stress
Interventions: LifeXT Program; Behavioral
Lead sponsor: American Heart Association; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Macon, Georgia • Chicago, Illinois

Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions: pegfilgrastim, cisplatin, ifosfamide, paclitaxel; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Erythrocytosis, Pulmonary Hypertension, Thrombosis
Interventions: Belzutifan; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Urinary Incontinence
Interventions: UISH001, matching placebo; Drug
Lead sponsor: Beech Tree Labs, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Endwell, New York • Rochester, New York • Upper Saint Clair, Pennsylvania

Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions: NS-229, Placebo; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Denver, Colorado • Rochester, Minnesota • Cleveland, Ohio + 4 more

Conditions: Tuberculosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases
Interventions: Empagliflozin, Placebos; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Dry Eye Disease, Dry Eye Syndrome
Interventions: SJP-0132, Placebo; Drug
Lead sponsor: Senju Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 65
States / cities: Los Angeles, California • San Diego, California • Tarzana, California + 53 more

Conditions: Gastrointestinal Health
Interventions: VIOME Precision Nutrition Program, VIOME-designed condition-based supplements; Combination Product · Dietary Supplement
Lead sponsor: Viome; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Hidradenitis Suppurativa
Interventions: antibiofilm surfactant wound gel (ABWG); Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Communicating About Choices in Transplantation

Telemedicine Brain Injury Coping Skills (BICS-T) Support Group for Brain Injury Survivors and Their Caregivers

"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

Escitalopram for the Treatment of Self-Injurious Skin Picking

Addressing Disparities in Diabetes Care

Home Use of Automatic External Defibrillators to Treat Sudden Cardiac Arrest

A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

Topical NanoDox® for Atopic Dermatitis

Oral Peanut Immunotherapy for Peanut Allergic Patients

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy

UW ISeqU: Clinical Impact of Whole-genome Sequencing in Adults

Improving Office Based Treatment of Opioid Use Disorder With Technology

Are Mindfulness Programs in the Workplace Effective at Reducing Stress

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis

Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions

Hidradenitis Suppurativa (HS) Tunneling Wounds